Rhythm Biosciences marked a pivotal shift from development to commercial diagnostics in Q3 FY26, recording its first ColoSTAT® clinical sale and initiating NHS England evaluation while expanding geneType™ partnerships across Asia and Australia.
- First ColoSTAT® clinical test sale achieved
- NHS England analytical evaluation commenced
- Quansys manufacturing agreement secures scale
- 4Cyte national pathology network activated
- Expanded geneType™ partnerships in Southeast Asia and Australia
Commercialisation Milestone Achieved with First ColoSTAT® Sale
Rhythm Biosciences Ltd (ASX:RHY) has crossed a significant threshold in its transformation into a commercial diagnostics company by recording its first clinical sale of ColoSTAT®, a blood-based colorectal cancer detection test. This inaugural transaction, completed in Q3 FY26, validates the clinical adoption of ColoSTAT® and confirms the operational readiness of the company’s laboratory and accreditation infrastructure. While initial test volumes remain modest, the sale signals a functioning commercial engine, with Rhythm now focused on scaling physician engagement and test volumes through its Access Program.
This milestone builds on the company’s recent regulatory success, including the completion of the NATA audit in January 2026, which certified Rhythm’s compliance with ISO 15189:2022 standards essential for in-house IVD testing. The company’s ability to generate revenue from ColoSTAT® marks a turning point after years of development and validation efforts, setting the stage for broader market penetration.
Rhythm’s ColoSTAT® commercial journey is supported by the activation of 4Cyte’s national pathology collection network, which facilitates convenient blood sample collection for patients across Australia, thus removing a critical logistical barrier to widespread adoption. The partnership with 4Cyte expands access points beyond the previously limited pathology centres, underpinning the company’s growth ambitions.
NHS England Evaluation Opens UK and European Pathways
In parallel with domestic progress, Rhythm has commenced an independent analytical evaluation of ColoSTAT® by an NHS England laboratory, marking a crucial step toward potential entry into the UK and broader European markets. The NHS, serving a population of 60 million, represents a rigorous testing ground whose endorsement could provide world-class validation and a commercial pathway for ColoSTAT® beyond Australia.
The evaluation, currently underway, will assess the analytical performance of the test in an independent setting, a process that could significantly influence clinician confidence and payer acceptance in international markets. This development aligns with Rhythm’s broader strategy to establish global partnerships and expand its diagnostic footprint.
Manufacturing and Distribution Infrastructure Secured
Rhythm has fortified its supply chain by executing a commercial manufacturing agreement with Quansys Biosciences, a specialist immunoassay manufacturer. This deal ensures scalable production of the multiplexed immunoassay reagents central to ColoSTAT®, addressing a key prerequisite for volume growth and commercial sustainability.
On the distribution front, the activation of the 4Cyte collection network complements the manufacturing scale, creating an integrated commercial infrastructure. This dual foundation of supply and access is critical for Rhythm as it transitions from pilot sales to routine clinical use.
geneType™ Expands Reach with New Partnerships and Enhanced Test
Alongside ColoSTAT®, Rhythm’s geneType™ platform, which offers polygenic and clinical risk assessments across multiple cancers and cardiovascular disease, has broadened its commercial footprint. New partnerships with Digistain Limited in Southeast Asia and the Australian Genome Research Facility (AGRF) domestically have extended distribution channels and customer access.
Notably, the first geneType™ commercial sale in Southeast Asia occurred shortly after the Digistain agreement, underscoring early traction in the region. The AGRF partnership leverages an established genomics reference laboratory network, providing a strategic boost to domestic growth amid rising demand for genomic risk information in clinical care.
Further enhancing geneType™’s clinical utility, Rhythm launched an upgraded colorectal cancer risk assessment test in January 2026. This enhanced version integrates additional clinical and lifestyle factors with the existing 140-SNP polygenic risk score, improving predictive accuracy particularly for women and younger adults at risk of early-onset colorectal cancer. The integration of geneType™ with ColoSTAT® creates a compelling ‘identify risk, detect disease’ continuum.
Financial Position Strengthened Amid Operating Cash Outflows
Rhythm’s financial footing was bolstered by the successful exercise and underwriting of RHYO options, providing additional working capital to support commercial activities. The company reported operating cash outflows of A$1.36 million for the quarter, consistent with ongoing investments in scaling test volumes and clinical engagement. Cash and cash equivalents stood at A$1.3 million at quarter-end, supplemented by A$85,000 in term deposits.
While the cash runway is under one quarter based on current operating cash flow, the company is actively pursuing further capital raising and managing costs to sustain operations. The recent options exercise and underwriting, detailed in the company’s earlier underwriting disclosure clarifications, provide a near-term buffer as Rhythm advances its commercialisation strategy.
Milestones Delivered and Next Steps
Rhythm met all its Q3 FY26 milestones, including NATA accreditation, commercial launch of the enhanced geneType™ CRC risk test, activation of the 4Cyte network, and commencement of the NHS England evaluation. The company’s focus for Q4 FY26 is clear: accelerate ColoSTAT® test volumes through expanded clinical engagement and the 4Cyte network, progress the NHS evaluation toward completion, and grow geneType™ partnerships internationally.
This momentum follows the company’s earlier validation of ColoSTAT®’s clinical pathway and regulatory framework, as reported in ColoSTAT® test pathway validation and NATA accreditation achievement(6798e5bf-f1c9-4903-9c47-c8036c877bd2b). The combined progress across regulatory, manufacturing, distribution, and clinical fronts positions Rhythm as a commercial player in the competitive cancer diagnostics landscape.
Bottom Line?
Rhythm’s successful first ColoSTAT® sale and NHS evaluation launch mark a commercial inflection point, but sustaining growth hinges on scaling test volumes and securing further capital amid tight cash reserves.
Questions in the middle?
- How will the NHS England evaluation results influence ColoSTAT®’s international market entry?
- What strategies will Rhythm deploy to accelerate ColoSTAT® test volume growth beyond initial modest sales?
- Can Rhythm secure additional funding to extend its cash runway and support expanding commercial operations?